Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma
Authors
Keywords
-
Journal
CANCER SCIENCE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-06-25
DOI
10.1111/cas.14541
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers
- (2020) Kazuo Okadome et al. BRITISH JOURNAL OF CANCER
- High expression of HLA-DQA1 predicts poor outcome in patients with esophageal squamous cell carcinoma in Northern China
- (2019) Fang-Fang Shen et al. MEDICINE
- Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.
- (2019) Takashi Kojima et al. JOURNAL OF CLINICAL ONCOLOGY
- KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer
- (2019) Ken Kato et al. Future Oncology
- Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors
- (2019) Yutaka Fujiwara et al. CANCER SCIENCE
- Tumour-associated macrophages are associated with poor prognosis and programmed death ligand 1 expression in oesophageal cancer
- (2019) Taisuke Yagi et al. EUROPEAN JOURNAL OF CANCER
- Impact of tumor-infiltrating LAMP-3 dendritic cells on the prognosis of esophageal squamous cell carcinoma
- (2019) Junya Nishimura et al. Esophagus
- Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer
- (2019) Megan Greally et al. CLINICAL CANCER RESEARCH
- First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
- (2019) Neeta Somaiah et al. CLINICAL CANCER RESEARCH
- Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities
- (2019) Ruidi Jiao et al. OncoTargets and Therapy
- Morphological lymphocytic reaction, patient prognosis and PD‐1 expression after surgical resection for oesophageal cancer
- (2019) Y. Baba et al. BRITISH JOURNAL OF SURGERY
- Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
- (2019) Ken Kato et al. LANCET ONCOLOGY
- Harnessing NK Cells for Cancer Treatment
- (2019) Paola Minetto et al. Frontiers in Immunology
- Prognostic Role of Tumor-Infiltrating Lymphocytes in Esophagus Cancer: a Meta-Analysis
- (2018) Xiao Zheng et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Safety and Antitumor Activity of the Anti–Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma
- (2018) Toshihiko Doi et al. JOURNAL OF CLINICAL ONCOLOGY
- Implication of Highly Cytotoxic Natural Killer Cells for Esophageal Squamous Cell Carcinoma Treatment
- (2018) Kee Siang Lim et al. JOURNAL OF IMMUNOTHERAPY
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016
- (2018) et al. JAMA Oncology
- CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
- (2018) Yelena Y. Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting macrophages: therapeutic approaches in cancer
- (2018) Luca Cassetta et al. NATURE REVIEWS DRUG DISCOVERY
- Precision immunoprofiling by image analysis and artificial intelligence
- (2018) Viktor H. Koelzer et al. VIRCHOWS ARCHIV
- Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus
- (2018) Manish A. Shah et al. JAMA Oncology
- Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status
- (2018) Romain Cohen et al. JAMA Oncology
- Tumor-associated myeloid cells: new understandings on their metabolic regulation and their influence in cancer immunotherapy
- (2017) Chiara Porta et al. FEBS Journal
- Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
- (2017) Toshihiro Kudo et al. LANCET ONCOLOGY
- Tumour-associated macrophages as treatment targets in oncology
- (2017) Alberto Mantovani et al. Nature Reviews Clinical Oncology
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Myeloid-Derived Suppressor Cells
- (2017) Dmitry I. Gabrilovich Cancer Immunology Research
- PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer
- (2017) Taisuke Yagi et al. ANNALS OF SURGERY
- Biomarkers associated with checkpoint inhibitors
- (2016) G. Manson et al. ANNALS OF ONCOLOGY
- Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome
- (2016) Shuhei Ito et al. ANNALS OF SURGICAL ONCOLOGY
- Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling
- (2016) Andy J. Minn et al. CELL
- Microsatellite Instability as a Biomarker for PD-1 Blockade
- (2016) J. C. Dudley et al. CLINICAL CANCER RESEARCH
- Basis for molecular diagnostics and immunotherapy for esophageal cancer
- (2016) Joe Abdo et al. Expert Review of Anticancer Therapy
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
- (2016) Kaiyan Chen et al. Oncotarget
- LV305, a dendritic cell-targeting integration-deficient ZVex TM -based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response
- (2016) Tina Chang Albershardt et al. Molecular Therapy-Oncolytics
- CD38-Expressing Myeloid-Derived Suppressor Cells Promote Tumor Growth in a Murine Model of Esophageal Cancer
- (2015) T. A. Karakasheva et al. CANCER RESEARCH
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- PD-1 Blockers
- (2015) Jedd D. Wolchok CELL
- Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy
- (2015) D. Di Mitri et al. CLINICAL CANCER RESEARCH
- Nomograms in oncology: more than meets the eye
- (2015) Vinod P Balachandran et al. LANCET ONCOLOGY
- Clinical relevance of host immunity in breast cancer: from TILs to the clinic
- (2015) Peter Savas et al. Nature Reviews Clinical Oncology
- Combination cancer immunotherapies tailored to the tumour microenvironment
- (2015) Mark J. Smyth et al. Nature Reviews Clinical Oncology
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- T cell exclusion, immune privilege, and the tumor microenvironment
- (2015) J. A. Joyce et al. SCIENCE
- Circulating CD14+HLA-DR−/low myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC
- (2015) Haitao Huang et al. TUMOR BIOLOGY
- IL-6-stimulated CD11b+ CD14+ HLA-DR− myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus
- (2015) Miao-Fen Chen et al. Oncotarget
- Human leukocyte antigen G is associated with esophageal squamous cell carcinoma progression and poor prognosis
- (2014) Jianyong Zheng et al. IMMUNOLOGY LETTERS
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Esophageal Carcinoma
- (2014) Anil K. Rustgi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma
- (2013) Manabu Shigeoka et al. CANCER SCIENCE
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Alteration of HLA-F and HLA I antigen expression in the tumor is associated with survival in patients with esophageal squamous cell carcinoma
- (2012) X. Zhang et al. INTERNATIONAL JOURNAL OF CANCER
- Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13
- (2011) Rachel F. Gabitass et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma
- (2011) Yoshihiro Komohara et al. CANCER SCIENCE
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review
- (2010) Katsuhiko Nosho et al. JOURNAL OF PATHOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search